# Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes

> **NCT06239506** · — · UNKNOWN · sponsor: **Xiaoling Guan** · enrollment: 340 (estimated)

## Conditions studied

- Type 2 Diabetes
- Novel Brominated Flame Retardants
- Organophosphate Flame Retardants
- Fasting Plasma Glucose

## Interventions

- **OTHER:** no intervention

## Key facts

- **NCT ID:** NCT06239506
- **Lead sponsor:** Xiaoling Guan
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06239506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06239506, "Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06239506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*